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An external evaluation program for measuring the performance of laboratories testing for cytokines and
immune activation markers in biological fluids was developed. Cytokines, chemokines, soluble cytokine recep-
tors, and other soluble markers of immune activation (CSM) were measured in plasma from a healthy human
immunodeficiency virus (HIV)-seronegative reference population and from HIV-seropositive individuals as
well as in supernatant fluids from in vitro-stimulated human immune cells. The 14 components measured were
tumor necrosis factor (TNF) alpha, gamma interferon, interleukin-1 (IL-1), IL-2, IL-4, IL-6, IL-10, Rantes,
MIP-Ia, MIP-Ib, soluble TNF receptor II, soluble IL-2 receptor alpha, b2-microglobulin, and neopterin. Twelve
laboratories associated with the Adult and Pediatric AIDS Clinical Trial Groups participated in the study. The
performance features that were evaluated included intralaboratory variability, interlaboratory variability,
comparison of reagent sources, and ability to detect CSM in the plasma of normal subjects as well as the
changes occurring in disease. The principal findings were as follows: (i) on initial testing, i.e., before partic-
ipating in the program, laboratories frequently differed markedly in their analytic results; (ii) the quality of
testing of a CSM in individual participating laboratories could be assessed; (iii) most commercial kits allowed
distinction between normal and abnormal plasma CSM levels and between supernatants of stimulated and
unstimulated cells; (iv) different sources of reagents and reference standards frequently provided different
absolute values; (v) inexperienced laboratories can benefit from participating in the program; (vi) laboratory
performance improved during active participation in the program; and (vii) comparability between analyses
conducted at different sites can be ensured by an external proficiency testing program.
The appearance of new diseases, therapies, or technologies
often leads to new clinical laboratory measurements. This is
often accompanied by novel instrumentation and reagents.
Under these circumstances and until laboratory procedures
and reagents are standardized and laboratory leaders and tech-
nologists have been trained, laboratories may differ substan-
tially in analytic results with comparable samples, with result-
ant confusion and possible misinterpretation of clinical status.
Thus, external performance evaluation programs are usually
introduced to achieve better performance and comparability in
laboratory testing.
A good example occurred early in the spread of human
immunodeficiency virus (HIV) infection and AIDS. Measure-
ments of CD4 T-cell levels were found to be central to evalu-
ation of disease course and therapeutic decisions. However, no
national proficiency testing procedures were in place. AIDS
patients who were tested for CD4 levels at different locations
often reported that laboratories differed substantially in their
analytic results obtained by flow cytometry. Thus, investigator-
initiated programs such as the Multicenter AIDS Cohort Study
(MACS) (7) and the AIDS Clinical Trials Group (ACTG) (15)
under National Institute of Allergy and Infectious Diseases
(NIAID) auspices instituted successful external proficiency
testing programs that achieved satisfactory comparability of
peripheral blood lymphocyte subset measurements by flow cy-
tometry. Subsequently, the Centers for Disease Control and
Prevention and the College of American Pathologists intro-
duced flow cytometry proficiency testing programs. More re-
cently, an international program for quality assurance and
standardization of CD4, CD8, and CD3 measurements (the
QASI program) has been instituted (12). The ACTG has also
instituted a performance evaluation program for quantitative
HIV assays (11).
Immune system activation is increasingly recognized as a
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significant component of many diseases. Autoimmune disor-
ders with activation include rheumatoid arthritis (10), inflam-
matory bowel disease (17), and multiple sclerosis (8). Immune
activation has also been shown to be characteristic of aging,
depression, and possibly some forms of chronic fatigue syn-
drome and fibromyalgia (9).
The role of immune activation in the pathogenesis of HIV
and AIDS is receiving increasing attention. Cytokine levels in
body fluids are elevated, as are soluble products of cytokine
activity such as neopterin, b2-microglobulin (b2M), and cyto-
kine receptors (6). Furthermore, elevated levels of activation
markers in plasma have been shown to be excellent prognostic
factors in HIV infection, providing data comparable to but
distinct from those provided by CD4 T-cell measurements or
by viral load assays (5).
An external proficiency testing program for measurement of
neopterin and b2M, two important markers of immune activa-
tion, was instituted among the four centers participating in the
Multicenter AIDS Cohort Study. Over a period of several
years, shipments were distributed to participating laboratories,
with general agreement among three laboratories for both
b2M and neopterin assays. One laboratory, however, was not
able to master one of the assays or to obtain results that were
consistent with those from the other three sites. Such discrep-
ancies adversely affected the prognostic usefulness of such
laboratory measurements (5). This prior experience empha-
sized the need for external proficiency testing programs to
verify laboratory performance and to assess the suitability of
various reagent sources to meet the needs of patients and
physicians dealing with immune disorders.
In a separate series of earlier studies at the University of
California at Los Angeles (UCLA) (1, 2) many factors were
found to influence the outcome of assays for tumor necrosis
factor alpha (TNF-a), gamma interferon (IFN-g), neopterin,
soluble TNF receptor II (sTNF-RII), soluble interleukin-2 re-
ceptor alpha (sIL-2R), and b2M. Substantial differences in
apparent levels of analytes were frequently found when ELISA
kits from different manufacturers were used (2). Furthermore,
the analytic results from different lots of ELISA kits supplied
by a single manufacturer occasionally differed by as much as
50%. In some cases, differences were found in the standards
provided by separate manufacturers (2). In addition, it was
demonstrated that many cytokines and products/markers of
immune activation were stable on frozen storage and could be
shipped to participating laboratories. Thus, batch testing of
frozen stored samples is feasible. The findings indicated that
for longitudinal studies, the levels of cytokines and immune
activation markers in plasma or serum should be measured
using preverified reagents from one manufacturer. Further-
more, proficiency testing and external quality assurance pro-
grams can help to develop a needed consensus.
The need for uniformity in the standards for quantitative
assays is clearly apparent. International reference standards
are available for many cytokines (13, 14, 16) but are not avail-
able for soluble cytokine receptors or soluble activation mark-
ers. However, a 1995 report (4) noted substantial differences in
terms of sensitivity and results in 11 laboratories using a variety
of assays for TNF-a. Also, an earlier study (3) described sub-
stantial differences in commercial reagents and standards pro-
vided in ELISA kits for IL-2, IL-6, and TNF-a in 1992. That
report (3) ended with a plea for “real standardization of im-
mune assays for cytokine quantitation.” Progress and problems
in this area were reviewed in 1997 (19).
By 1996, the Adult and Pediatric ACTG programs had es-
tablished more than 15 immunology laboratories to evaluate
immunologic parameters relevant to HIV infection and its
therapy. Recommendations were made to the ACTG and the
Division of AIDS (DAIDS), NIAID, that an external profi-
ciency testing program be tried as a quality assurance proce-
dure for laboratory performance of cytokine and activation
marker measurements. Such a program was initiated in Janu-
ary 1997 and terminated in January 1999. Three separate ship-
ments of biological fluids were carried out. Plasma as well as
supernatant fluids from stimulated immune cells were evalu-
ated. Replicate samples were included to evaluate intralabo-
ratory variability. Assays for cytokines included TNF-a, IFN-g,
IL-1, IL-2, IL-4, IL-6, IL-10, and the chemokines Rantes, MIP-
Ia, and MIP-1b. Assays for levels of immune activation mark-
ers in plasma included neopterin, b2M, sTNF-RII, and sIL-2R.
A total of 11 laboratories participated. Quite remarkable dif-
ferences between laboratories became apparent in the analyses
of the first shipment. Significant problems were uncovered.
When these were addressed, more-uniform results were ob-
tained. The value of an external proficiency testing program
was documented.
MATERIALS AND METHODS
Participation. All of the Advance Technology Laboratories for the Adult
ACTG and the Immunology Research Laboratories of the Pediatric ACTG were
repeatedly invited to participate. Those that elected to participate and reported
results from the Adult ACTG program are listed in Table 1. The same laboratory
at UCLA (the Clinical Immunology Research Laboratory, Center for Interdis-
TABLE 1. Reporting sitesa
Site no. Site
Testing reports for study:
I II III
1 Rush Medical Center, Chicago, Ill. 2 1 1
2 UCLA 1 1 1
3 University of California, San Diego 1 1 1
4 University of Texas Medical Branch, Galveston 1 1 1
5 North Carolina Memorial Hospital 1 1 2
6 M.D. Anderson Cancer Center 1 2 1
7 Children’s Hospital, Philadelphia, Pa. 1 1 1
8 University of California, San Francisco 1 2 2
9 University of Washington Fred Hutchinson Cancer Research Center 2 1 2
10 University of Colorado Health Sciences Center 2 2 1
11 University of Miami School of Medicine 1 2 2
12 Albert Einstein College of Medicine 1 2 2
a Laboratories 2, 3, 6, 7, and 8 participated in the Pediatric ACTG program. Laboratories 1, 2, 4, 5, 9, and 10 participated in the Adult ACTG program. Laboratory
2 participated in both the Adult and Pediatric ACTG programs. Laboratories 11 and 12 were added at the request of DAIDS, NIAID.
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ciplinary Research in Immunology and Disease) participated in both the Adult
ACTG and Pediatric ACTG programs. The University of Miami School of
Medicine and Albert Einstein Medical Center, New York, N.Y., participated
briefly at the invitation of DAIDS, NIAID. Participation was defined as contrib-
uting analytic data on one or more of the sample shipments. Conference calls
were held regularly, starting in March 1997, by the ACTG Cytokine and Soluble
Marker (CSM) Focus Group, which constituted an advisory group for this pro-
gram.
Initial decisions were as follows. (i) EDTA plasma samples would be obtained
from both normal and HIV-positive individuals. (ii) Initially, the plasma cyto-
kines to be tested were TNF-a and IFN-g and the soluble markers of activation
were neopterin, sTNF-RII, b2M, and sIL-2R. Subsequently, tests for IL-1a, IL-2,
IL-4, IL-6, IL-10, and Rantes, MIP-1a, and MIP-1b were added. (iii) A number
of samples, including replicates, would be sent by FAST Systems, Inc. (Gaith-
ersburg, Md.) to each participating ACTG laboratory for testing. Samples from
HIV-negative and HIV-positive donors would be included, replicate samples
would be randomly distributed, and sample identification would be nondescrip-
tive. (iv) Laboratories would include these samples in their testing repertoire and
were not expected to initiate new assays or do assays for all of the markers in the
program but to concentrate on the ones which they were currently testing. (v)
Laboratories would indicate the source of reagents and the type of methodology
used for each test. (vi) Data would be reported directly to FAST Systems and
transferred to the ACTG Statistical and Data Analysis Center (SDAC), Harvard
School of Public Health, Boston, Mass., for evaluation of the data distribution
from individual laboratories, comparison of results from various reagent sources,
and consistency of individual laboratories on analyses of replicate samples. (vii)
Participating laboratories would receive a comprehensive report on the analytic
data obtained for each shipment. (viii) After the results of shipments were
analyzed and discussed, further plans for additional testing would be formulated,
appropriate samples would be obtained, and a new batch of proficiency testing
samples would be distributed. (ix) Subsequently, decisions were made to add
supernatants from phytohemagglutinin (PHA)- and from lipopolysaccharide
(LPS)-stimulated whole blood samples and from separated peripheral blood
mononuclear cells (PBMC) for testing.
Implementation. Large volumes of plasma were obtained by FAST Systems
from a number of seropositive and seronegative individuals. Levels of selected
cytokines and soluble markers were determined by the procedures and with the
reagents available at UCLA so that a range of levels could be selected. The
results were reported to FAST Systems, where a new coding system (known only
to them and to John Spritzler, SDAC) was introduced. John Spritzler (SDAC)
and Myron Waxdal (FAST Systems) determined the composition of the ship-
ments, and 1-ml aliquots were prepared for shipment.
Individuals responsible for receiving samples at each site were identified. A
preliminary notice was sent about 10 days before shipping with a request for a
signed response. This is a legal requirement because of the nature of the ship-
ment of infectious materials.
Quantitation of plasma levels of cytokines and soluble activation markers.
b2-Microglobulin was quantified using microparticle enzyme immunoassay (mi-
croparticle EIA) (Abbott Laboratories, Abbott Park, Ill.) and enzyme immuno-
assay (EIA) kit (Coulter, Miami, Fla.). Neopterin was measured with a compet-
itive EIA kit (ELI test; BRAHMS, Berlin, Germany). sIL-2R was determined
with EIA kits (Endogen Inc., Cambridge, Mass., and Immunotech, Marseilles,
France). sTNF-RII was quantitated in plasma at a 1:20 dilution by using EIA kits
(HyCult, Uden, The Netherlands; R&D Systems, Minneapolis, Minn.; and Med-
genix, Fleurus, Belgium). TNF-a was measured with EIA kits (Medgenix; Inno-
genetics, Zwijndecht, Belgium; Endogen; Biosource International; and Gen-
zyme). IL-10 was measured with EIA kits (from Immunotech, from Endogen and
from Biosource International). IFN-g was determined by using EIA kits with and
without the CIRID at UCLA modification of the manufacturer’s protocol (Im-
munotech, Endogen, Biosource International, Genzyme, T-Cell Diagnostics, and
R&D Systems). IL-2, IL-4, IL-6, and RANTES were each measured with EIA
kits from Endogen and from Biosource International. MIP-1a and MIP-1b were
measured with R&D System’s Quantikine EIA kits. All assays were performed
according to the manufacturer’s instructions.
Shipments. (i) On 30 September 1997, six aliquots of plasma were sent to
participating laboratories. There were three aliquots (replicates) of a single
normal plasma and one sample each from three HIV-seropositive individuals.
Reports were collected in October, November, and December 1997. Analyses
included TNF-a, IFN-g, IL-2, IL-10, b2M, neopterin, sTNF-RII, and sIL-2R.
The data were analyzed at SDAC (Harvard School of Public Health) and shared
with participating laboratories in the following months.
(ii) On 30 March 1998, 10 supernatant fluids from PHA-, LPS-, or mock-
stimulated whole blood or separated PBMC from HIV-seropositive and HIV-
seronegative individuals (which had been prepared at UCLA and transferred to
FAST Systems for coding and aliquoting) were shipped to participating sites.
Analyses were conducted and data were collected in April, May, June, and July
1998, evaluated, and shared with participating laboratories.
(iii) On 30 September 1998, 12 samples were shipped to participating labora-
tories. These included six plasma samples and six stimulated lymphoid cell
supernatant fluid samples from HIV-seronegative and HIV-seropositive individ-
uals. Three replicates were included in the stimulated cell supernatant group.
Data were collected in October, November, and December 1998 by FAST Sys-
tems and analyzed at SDAC.
Statistical procedures. Analytic data from participating sites were collected by
FAST Systems in the months after each shipment and transferred to SDAC,
Harvard School of Public Health. Results that were below the limit of detection
were indicated as zero on the plots but were excluded from calculations of means
and coefficients of variation.
RESULTS
Study I: HIV-seronegative and -seropositive plasma sam-
ples. Results were received from nine laboratories (Table 1).
Three laboratories tested six analytes, four laboratories tested
three analytes, one laboratory reported two assays, and one
laboratory reported only one assay. Replicate samples (three)
of an HIV-seronegative plasma were included in the shipment.
These results are plotted in Fig. 1 as the first three samples, but
they were in fact not distributed in sequence among the six
samples. Mean levels of tested analytes at different laborato-
ries are presented in Fig. 2A, and calculated coefficients of
variation are shown in Table 2. Three HIV-seropositive plasma
samples with various degrees of abnormalities are included in
Fig. 1 as well.
Examples of the findings are illustrated in Fig. 1. Two lab-
oratories were able to measure plasma neopterin levels in
normal samples and obtained similar data in three replicates
(Fig. 1A). Also, these two laboratories determined that the
HIV-positive samples had a higher neopterin content than the
HIV-negative samples, and they were able to detect differences
between the three HIV-positive samples. These three features
are evidence of good laboratory performance. However, a
striking difference between the quantitative neopterin data is
evident (Fig. 1A). This could be due to reagent features or
differences in the reference standards provided by the manu-
facturer (11). Similar findings were noted for b2M when results
from three laboratories were evaluated (data not shown).
Somewhat similar findings were evident in four laboratories
(B, C, E, and F) testing for sTNF-RII (Fig. 1B); e.g., there
were consistent values for replicate samples, higher levels in
HIV-positive than in HIV-negative samples, but great differ-
ences in quantitative results between labs. Furthermore, one
laboratory (F) was barely able to detect sTNF-RII in the HIV-
positive samples. In the sIL-2R analyses, six of seven labora-
tories detected sIL-2R in normal plasma and all labs detected
higher levels in HIV-positive samples, but quantitative agree-
ment was poor (data not shown).
Problems were more evident in TNF-a testing (Fig. 1C),
where four laboratories (A, D, F, and H) were unable to detect
this analyte in the HIV-negative sample. Two laboratories (A
and D) could not detect TNF-a in any of the HIV-positive
samples, and another lab (F) could detect it in only one sam-
ple. In contrast, two laboratories (C and E) had consistent
values for the replicate samples and identified appreciable
elevations in the HIV-positive samples. However, one labora-
tory (B) did not find differences between the HIV-negative and
HIV-positive samples. Similar problems were seen with IFN-g,
where five of seven laboratories could not detect this in any
samples (Fig. 2A). Several of these laboratories were just in-
stituting these tests and had procedural or reagent problems
which were identified during group discussions with staff at the
more experienced sites. On further testing with improved pro-
cedures and/or with use of more appropriate reagent sources,
results at these sites became comparable to those of other
laboratories.
The CSM results in study I were evaluated by conference call
and at a CSM study team gathering at an Advance Technology
Laboratories meeting. The performance of different test re-
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agents was evaluated for sensitivity, accuracy, and reproduc-
ibility (1, 2). For instance, although the manufacturer’s re-
ported sensitivity for all reagents was at or below 5 pg/ml,
significant differences were noted when the reagents were
tested in this study. The following reagent sources were rec-
ommended as preferred reagent sources for plasma testing of
cytokines and soluble activation markers: TNF, Medgenix;
IFN-g, Immunotech; sTNF-RII, HyCult and Medgenix; sIL2R,
Endogen and Immunotech, b2M, Abbott microparticle EIA
(non-ELISA) procedures; and neopterin, ELI test
(BRAHMS). It must be noted that not all available reagent
sources were tested or compared. Also, the more sensitive
versions of TNF-a and IFN-g assays were not evaluated.
Study II: supernatant fluids. A total of 10 samples were
shipped to seven sites. These included three replicates of a
72-h PHA-stimulated PBMC supernatant (samples 1, 4, and 8)
and four nonstimulated samples (samples 2, 3, 6, and 9). One
PHA-stimulated whole blood cell supernatant (sample 7) and
two LPS-stimulated cell supernatants (sample 5 from PBMC
and sample 10 from whole blood) are included. A total of nine
markers (IFN-g, TNF-a, IL-2, IL-4, IL-6, IL-10, MIP-1a, MIP-
1b, and Rantes) were measured using reagents from five
sources. Representative results are presented in Fig. 3.
All five laboratories that reported results were consistent
with the replicate analyses of IFN-g (Fig. 3A and Table 2).
Laboratories A, C, and K were in good agreement throughout.
However, lab D used a different kit and had much lower values,
and lab F had at least one aberrant result.
TNF-a analyses were quite consistent in labs C and D. How-
ever, lab A showed variation in the replicates (Fig. 3B and
Table 2) and indicated stimulation in sample 9.
IL-2 results varied (Fig. 3C and Table 2). Two labs (D and J)
did not detect IL-2 in any of the samples, and lab K reported
similar levels in stimulated and many nonstimulated superna-
tants. Laboratory A results varied substantially for the repli-
cates as well as for the nonstimulated samples. IL-4 levels in
FIG. 1. Analytic data from study I for neopterin (A), sTNF-RII (B), and TNF-a (C) measured in several laboratories (designated by capital letters). Three aliquots
(triplicates) of plasma (samples 1, 4, and 5) from a single seronegative donor were included, and the data are grouped on the left. Results for three plasma samples
(samples 2, 3, and 6) from different HIV-seropositive donors are presented on the right.
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the replicates varied in three labs as well as in the stimulated
and nonstimulated samples (data not shown). There was gen-
eral dissatisfaction with the IL-4 assays. Replicate agreement
was good in two laboratories (A and D) reporting IL-6 analy-
ses, but some discrepancies in stimulated and nonstimulated
levels were evident (data not shown).
All three labs (C, D, and J) reported elevated IL-10 lev-
els in the three replicate and LPS-stimulated supernatants
(data not shown). One lab (J) showed significant variability
(Table 2). Unfortunately, there were major (but consistent)
differences in the quantitative data from the three labora-
tories.
Rantes was tested in three laboratories (D, I, and K) using
the same reagent source (Fig. 3D). Good replicate values and
similar quantitative levels were reported. All performed well
with replicates. However, a second assay source evaluated in
lab K showed increased variability (Table 2) and failed to
reveal differences between stimulated and nonstimulated
samples. MIP-Ia and MIP-Ib were tested in only one labora-
tory, where replicate samples agreed well and higher levels
were found in stimulated samples than in controls (data not
shown).
Overall, most laboratories performed well with the repli-
cates for almost all cytokines and chemokines. One laboratory
had some difficulties. Reagents from a single source generally
gave similar results when tested in several different labora-
tories. In some assays, reagent sources differed substantially,
indicating the need to address reference standard and/or
calculation issues. IL-2 and IL-4 varied so much that levels
at or below limits of detection were suspected for many
samples.
FIG. 2. Mean levels of cytokines, chemokines, and soluble products of immune activation reported by individual laboratories (designated by capital letters). Mean
levels from triplicate samples of normal plasma in study I (A) and supernatant fluid from PHA-stimulated PBMC in study III (B) are presented for the laboratories
that reported data. Assay values for all analytes are in picograms per milliliter.
TABLE 2. Variability of tests on three replicate samples included
in each shipment
Laboratory
CV (%)a for assay of:
TNF-a IFN-g IL-2 IL-10 RANTES
A 2/41/21 2/15/8 /136/
B 33// 2//
C 5/11/5,8 50/3/3 //38 /10/10 //6
D 2/12/8 2/15/5 /2/2 /9/10 /2/8
E 25//
F 2// 2/7/




K //12 /11/11 /25/19 /15,27/6
L //2 //48
a Results are presented as coefficients of variation (CV) for all three shipments
(first/second/third). 2, analyte was tested but not detectable. The absence of
number indicates that test was not done. For example, laboratory A, did not
detect TNF-a in the replicates in the first shipment but did in the second (with
a CV of 41%) and in the third (with a CV of 21%). Laboratory B did test TNF-a
in the first shipment but did not in the second and third shipments.
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Study III. Six supernatant samples (1 to 6), including three
replicates and six different plasma samples, were included in
this study. Two or more laboratories reported analyses for
TNF-a, IFN-g, IL-2, IL-4, IL-10, and Rantes. Values for IL-6,
MIP-Ia, MIP-Ib, sIL-2R, sTNF-RII, neopterin, and b2M were
reported from individual laboratories.
TNF-a analyses of both control and poststimulation super-
natant samples are presented in Fig. 4A. Mean values of the
triplicate repeats for five different labs are shown in Fig. 2B.
The replicates of a supernatant were tested in three laborato-
ries (C, D, and K) using the same reagent sources (Table 3). A
second reagent source was also used in laboratory C, and
laboratory A used a third source. This last source gave much
lower values and missed the TNF-a in plasma.
Overall, the replicate values were consistent in each labora-
tory, and all laboratories detected the differences between
stimulated and nonstimulated supernatants. Three laborato-
ries (D, K, and C) detected plasma differences between sero-
positive and seronegative donors, although one lab (A) failed
to do so. There were some differences in absolute values, but
the differences between laboratories were quite consistent.
IFN-g analyses (Fig. 4B) showed good replicate agreement
in six laboratories (A, C, D, G, K, and I) but not in one (L)
(Table 2). All laboratories distinguished stimulated from non-
stimulated supernatants. One lab (C) identified elevated IFN-g
levels in the tested plasmas of the three HIV-seropositive do-
nors, but two labs (D and K) did not detect any IFN-g. Labs A
and L reported detectable IFN-g in all plasma samples but
with no difference between HIV-negative and HIV-positive
samples. The three HIV-seropositive plasma samples all re-
vealed elevated levels of b2M, neopterin, sIL-2R, and sTNF-
RII in comparison to the seronegative samples (data not shown).
Rantes analyses (Fig. 4C) of supernatant replicates and
other supernatant samples, including a control, showed good
FIG. 3. Analytic data from study II for IFN-g (A), TNF-a (B), IL-2 (C), and Rantes (D) measured in several laboratories (designated by capital letters). Three
replicate sample (triplicate samples 1, 4, and 8) obtained from a PHA-stimulated 72-h supernatant are grouped on the left. Four samples (samples 2, 3, 6, and 9) were
not stimulated. One PHA-stimulated whole blood supernatant (sample 7) and two LPS-stimulated cell supernatants, one from PBMC (sample 5) and one from whole
blood (sample 10), are included. K and K9 designate results from laboratory K using two different reagent sources.
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agreement in four laboratories (C, D, K, and I) (Table 2). The
quantitative differences were consistent (Fig. 2B), but the rea-
son for the differences was not apparent because all labs used
the same reagent source.
Replicate sample results (coefficients of variation) were
good in almost all laboratories for all 13 components tested for
each lab (good was defined as a coefficient of variation less
than 20%). This indicated that laboratory performance was
quite high. However, differences in quantitative values per-
sisted.
Coefficients of variation for the tests done on replicate sam-
ples in two or more shipments are assembled in Table 2.
Improvement in performance by study III is seen in most
laboratories for TNF-a, IFN-g, and Rantes. The greatest vari-
ability was seen with IL-2.
Differences in the mean levels reported by laboratories for
10 cytokines and other markers are indicated in Fig. 2. Failure
by several laboratories early in the proficiency program to
detect TNF-a and IFN-g in normal plasma is illustrated in Fig.
2A. Also, a wide difference was seen between some labs (for
TNF-a and IFN-g), but good agreement was seen between
others (for sIL-2R). In Fig. 2B, however, general agreement in
levels is seen with a number of assays.
The different values seen in Fig. 2 could be due to the
reagent sources. This possibility was evaluated for IFN-g and
IL-2 (Table 3). For IFN-g, Endogen kit results tended to be
lower than Immunotech results. If laboratory I used the wrong
decimal point, the corrected value would be 9,640 pg/ml, which
would be near the level reported by laboratory C. Thus, for
IFN-g, the Immunotech kit was better than Endogen kits, with
lower intralaboratory (Table 3) and interlaboratory coefficients
of variation. Furthermore, in testing of the same normal
plasma control samples, Endogen kits were consistently unable
to detect any level of IFN-g, while Immunotech kits detected
FIG. 4. Analytic data from study III for TNF-a (A), IFN-g (B), and Rantes (C) measured in several laboratories (designated by capital letters). Three replicates
of a stimulated PBMC supernatant (samples 1, 3, and 5) are grouped on the left. Three other supernatants (stimulated [samples 2 and 6] and nonstimulated [sample
4]) are presented. C and C9 designate results from laboratory C using two different reagent sources.
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an average of 14.9 pg/ml. For IL-2, the Biosource kits indicated
higher levels than the Endogen data. However, substantial
differences between laboratories in IL-2 mean levels were ev-
ident.
The intralaboratory variability was not unusual for TNF-a,
IFN-g, and Rantes (Table 3). Laboratory performance by this
criterion does not account for the differences in mean values
for IFN-g or Rantes. Differences could be in the manner of
using reference standards. However, separate from the stan-
dard issue, the tests for IL-2 showed substantially greater vari-
ability in performance than any of the other assays.
DISCUSSION
An external evaluation program to assure quality perfor-
mance of many clinically important assays is required of labo-
ratories participating in the College of American Pathologists
accreditation program. New assays, however, may not be in-
cluded in these programs until a need is established, usually by
extensive use in clinical practice. Proficiency testing programs
for plasma cytokines, chemokines, and the soluble markers of
immune activation are not in place.
The findings presented here emphasize the importance of
having a well designed and critically evaluated external perfor-
mance evaluation program when measurements are clinical
relevant and are to be conducted at multiple sites. Levels of
cytokines, chemokines and soluble products of immune acti-
vation are increased in many autoimmune and inflammatory
disorders and in HIV infection and are altered by aging (18;
J. L. Fahey, J. F. Schnelle, J. K. Thomas, M. E. Gorre, N. Aziz,
and P. Nishanian, submitted for publication). Increasingly, im-
mune-based therapies are designed to alter cytokine activities.
Initially, in the first study, laboratory performance was un-
even as was evident with the results for replicate samples at
several sites. This proved to be due to inexperience, inade-
quate supervision, misunderstanding of procedures, and other
reasons. However, after discussions led by experienced labo-
ratory personnel, difficulties were addressed, and replicate val-
ues were better by the third study. However, there were labo-
ratories where the experienced technician left to go to
graduate school or other employment and the process of ed-
ucation and training began again.
Differences in reagents and standards between suppliers was
a more resistant problem. Because international standards are
available for almost all cytokines, it was surprising to find
marked differences within the cytokine measurements. On the
other hand, the capacity for errors in laboratory performance
is almost limitless. However, there was a group of laboratories,
using the same supplier, which usually had comparable results.
International standards are not yet available for the soluble
receptors and other products of immune activation. Thus, it is
probably advisable to identify a single source of reagents and
standards for each assay after their usefulness has been veri-
fied.
We did not find one reagent supplier superior to all the
others, but the study was not designed to test all suppliers or
reagents kits. In general when several were compared, one or
two sources appeared to be more useful. However, we have
had the experience of major changes in the quality of a reagent
or in a reference standard from a single reagent manufacturer
(2).
The distinction between an external proficiency testing pro-
gram for performance evaluation and the provision of inter-
national reference standards, such as for cytokines, is impor-
tant. International standards are used for calibration of
reference materials. In contrast, external proficiency testing
programs assess actual assay performance and allow laboratory
evaluation. Many labs assume that they are doing good work,
but participation in an external proficiency testing program is
a means of proving it. Also, participation in well-run external
proficiency testing programs for performance evaluations can
help new, inexperienced, or otherwise disadvantaged labora-
tories to achieve high performance levels by consultation with
more experienced personnel.
The premise in undertaking this external proficiency testing
program was that laboratories which were funded to support
multicenter clinical therapeutic trials might not provide similar
values for tests of cytokines and soluble markers of immune
activation (CSM). At the time that the studies were begun,
CSM testing was still evolving rapidly, with many putative
suppliers of reagents and standards and a variety of techniques.
No proficiency testing programs for performance evaluations
were in place, and some laboratories had not established meth-
ods or quality assurance procedures. A corollary assumption
was that laboratories that participated would benefit from the
experience. An obverse corollary would be that laboratories
that did not participate might well have unrecognized prob-
lems. Deficient laboratory performance is documented in other
studies (3, 4).
The experience reported here indicates the potential value
of an external proficiency testing program for CSM on a larger,
conceivably national, scale. The need reaches across many
areas of adult and pediatric medicine. Physicians can use im-
munologic tests for cytokines and for the products of cytokine
activity in the evaluation of many autoimmune diseases, of
infectious diseases affecting the immune system (such as HIV
infection), and of other disorders characterized by changing
balances within the immune system. Furthermore, quality eval-
uations of relevant immune activities are essential for moni-
TABLE 3. Laboratory levels and intralaboratory coefficients
of variationa



















IL-10 D1 33 10.4
G1 134 21.9




a Triplicate sample data in study III.
b Letters indicate laboratories, and numbers indicate reagent sources (1, Bio-
source; 2, Endogen; 3, Immunotech; 6, Medgenix; 9, Innogenetics).
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toring therapies designed to activate or suppress immune
functions.
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